Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice

Authors

Sarah C Hurt, Washington University School of Medicine in St. Louis
Steven Q Le, Washington University School of Medicine in St. Louis
Shih-Hsin Kan, Children's Hospital of Orange County
Quang D Bui, Lundquist Institute for Biomedical Innovation
Michael D Brodt, Washington University School of Medicine in St. Louis
Patricia I Dickson, Washington University School of Medicine in St. Louis

Journal

Molecular Therapy Methods & Clinical Development

Publication Date

3-13-2025

Volume

33

Issue

1

First Page

101405

Document Type

Open Access Publication

DOI

10.1016/j.omtm.2024.101405

Rights and Permissions

Hurt SC, Le SQ, Kan SH, Bui QD, Brodt MD, Dickson PI. Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice. Mol Ther Methods Clin Dev. 2025 Jan 2;33(1):101405. doi: 10.1016/j.omtm.2024.101405. Copyright 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Hurt, Sarah C; Le, Steven Q; Kan, Shih-Hsin; Bui, Quang D; Brodt, Michael D; and Dickson, Patricia I, "Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice." Molecular Therapy Methods & Clinical Development. 33, 1. 101405 (2025).
https://digitalcommons.wustl.edu/oa_4/5517

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.